Canadian Solar vs Microchip Technology
CSIQ and MCHP side by side, both in electronic components and accessories. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CSIQ and MCHP compare
Microchip Technology grew revenue faster over the last twelve months (20.9% versus −6.6% for Canadian Solar).
Microchip Technology keeps more of each dollar of sales as profit, with a net margin of 9.3% compared with −1.9% at Canadian Solar.
Microchip Technology pays a dividend yielding 3.1%; Canadian Solar does not pay one.
Microchip Technology scores higher on the StockData Score (12 against 3 for Canadian Solar), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CSIQ | MCHP |
|---|---|---|
| Size and price | ||
| Market cap | – | $32.3B |
| Share price | $7.80 | $59.43 |
| Change, 1 year | −76.8% | 11.1% |
| Change, 5 years | −79.6% | −25.8% |
| Beta (5Y) | 1.48 | 2.63 |
| Employees | 1,318 | 18K |
| StockData Score | ||
| Total score | 3 | 12 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 3 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 2 | 4 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | – | 88.7× |
| P/S | – | 6.3× |
| P/B | – | 5.0× |
| EV/EBITDA | – | 25.4× |
| P/FCF | – | 29.0× |
| FCF yield | – | 3.4% |
| Fair value | – | $30.92 |
| Margin of safety | – | −92.2% |
| Growth | ||
| Revenue growth (TTM) | −6.6% | 20.9% (better) |
| Revenue growth, 5Y average | 10.0% (better) | −2.8% |
| Net income growth (TTM) | −389% | – |
| EPS growth (TTM) | −563% | – |
| EPS growth, 5Y average | – | −19.5% |
| Profitability | ||
| Gross margin | 18.3% | 60.2% (better) |
| Operating margin | 0.77% | 15.5% (better) |
| Net margin | −1.9% | 9.3% (better) |
| FCF margin | −21.7% | 21.7% (better) |
| Return on equity | −3.7% | 7.2% (better) |
| Return on invested capital | 1.0% | 5.6% (better) |
| Financial health | ||
| Debt / equity | 0.85 | 0.83 (better) |
| Net debt / EBITDA | 1.70 (better) | 3.46 |
| Interest coverage | 0.2× | 3.7× (better) |
| Current ratio | 1.02 | 1.92 (better) |
| Altman Z-score | – | 3.54 |
| Piotroski F-score | 2 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 3.1% |
| Payout ratio | – | 206% |
| Years of dividend growth | – | 17 |
| Dividend growth, 5Y average | – | 19.5% |
| Buyback yield | – | −0.19% |
| Shareholder yield | – | 2.9% |
| Ownership | ||
| Held by institutions | 60.1% | 100% |
| Held by insiders | 37.3% | 2.0% |
| Insider net buying, 12 months | −$63.0K (better) | −$70.9M |
| Superinvestors holding | – | 2 |
| Short interest, % of float | 45.7% | – |
Go deeper
- CSIQ stock overview
- CSIQ income statement
- CSIQ valuation and score
- MCHP stock overview
- MCHP income statement
- MCHP valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.